Micro Developing Active

Eli Lilly expande el acceso a Zepbound para el crecimiento a largo plazo

Puntuación
0,5
Velocidad
▲ 0,0
Artículos
9
Fuentes
4

Resumen

Un artículo pertenece a esta narrativa si discute la expansión del acceso a Zepbound por parte de Eli Lilly y sus perspectivas de crecimiento a largo plazo.

Artículos Relacionados

Jim Cramer Likes Eli Lilly’s (LLY) New Deal

Yahoo Finance · Abr 05, 2026
Mixed

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Nasdaq · Abr 04, 2026
Mixed

Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know

CNBC · Abr 01, 2026
Mixed

The cutthroat battle for the US weight-loss drug market

BBC Business · Mar 23, 2026
Mixed

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook

Yahoo Finance · Mar 22, 2026
Mixed

Fuentes

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of … Nasdaq
Jim Cramer Likes Eli Lilly’s (LLY) New Deal Yahoo Finance
Is Eli Lilly and Company (LLY) The Best Pharma Stock … Yahoo Finance
Eli Lilly secures long-awaited FDA approval for its obesity pill. … CNBC
Eli Lilly reaches $2.75 billion deal with Insilico to bring … CNBC
Here's How Much Upside Eli Lilly Stock Has, According to … Yahoo Finance
The cutthroat battle for the US weight-loss drug market BBC Business
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing … Yahoo Finance

Cronología

Última actualización Mar 22, 2026